Terasaki Foundation Laboratory, Los Angeles, CA, USA; Division of Liver and Pancreas Transplantation, Department of Surgery, University of California, Los Angeles, CA, USA.
J Immunol Res. 2017;2017:3234906. doi: 10.1155/2017/3234906. Epub 2017 Jan 9.
More than ten years after the initial description of the humoral theory of transplantation by Dr. Paul I. Terasaki, the significance of humoral alloimmunity in liver transplantation has yet to be clearly defined. The liver allograft has an inherent tolerogenic capacity which confers its resistance to cell-mediated as well as antibody-mediated rejection. Nevertheless, the protection against alloimmunity is not complete, and antibody-mediated tissue injury can occur in the liver graft under specific circumstances. In this article the evidence on the clinicopathologic effects of donor-specific alloantibodies in liver transplantation will be examined and interpreted in parallel with lessons learned from renal transplantation. The unique anatomic and immunologic features of the liver will be reviewed to gain new insights into the complex interactions between humoral immune system and the liver allograft.
在 Paul I. Terasaki 博士最初描述移植的体液理论十多年后,体液性同种异体免疫在肝移植中的意义仍未得到明确界定。肝移植物具有内在的耐受能力,使其能够抵抗细胞介导和抗体介导的排斥反应。然而,对同种异体免疫的保护并不完全,在特定情况下,抗体介导的组织损伤可能发生在肝移植物中。本文将检查和解释在肝移植中供体特异性同种抗体的临床病理影响的证据,同时借鉴肾移植的经验教训。将回顾肝脏的独特解剖和免疫学特征,以深入了解体液免疫系统与肝移植物之间的复杂相互作用。